Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01670773 · ClinicalTrials.gov registry record · Phase 1

A Study of CAT-1004 Biomarkers in Healthy Subjects

A Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans, sponsored by Catabasis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT01670773: Completed Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans, sponsored by Catabasis Pharmaceuticals.

NCT01670773 is a Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01670773, a Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans, has completed, sponsored by Catabasis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.

Interventions

  • DRUG Placebo
  • DRUG CAT-1004
  • DRUG Salsalate + DHA

Study Locations (1)

Massachusetts

  • ProMedica - Brighton

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2012-08
Est. Completion 2012-10
Phase Phase 1
Catabasis Pharmaceuticals

12 total trials

What the finished NCT01670773 record still lists

NCT01670773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Assessment of Mechanistic Blood Biomarkers in Healthy Humans appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01670773 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01670773 about?

NCT01670773 is a clinical study titled "A Study of CAT-1004 Biomarkers in Healthy Subjects". This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.

What is the current status of trial NCT01670773?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-08. Estimated completion is 2012-10.

What conditions does trial NCT01670773 study?

This clinical trial studies the following conditions: Assessment of Mechanistic Blood Biomarkers in Healthy Humans.

What interventions are being tested in trial NCT01670773?

The interventions under investigation include: Placebo (DRUG), CAT-1004 (DRUG), Salsalate + DHA (DRUG).

Who is sponsoring clinical trial NCT01670773?

This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01670773 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01670773's enrollment target sits among peer trials

9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01670773, the US trial registry maintained by the National Library of Medicine. NCT01670773 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.